Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FC-12738 SAD in Healthy Adults and ALS Patients
NCT05978908Phase 1Completed
- Sponsor
- Neurodegenerative Disease Research, Inc.
- Start
- Feb 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing FC-12738 with Placebo (2 arms). Primary endpoints: Safety and Tolerability at Day 8, Blood Pressure at Day 8 and 7 more. Started Feb 2024; status: completed.
02
Drugs
FC-12738
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05978908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978908.